These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 25966433)

  • 1. Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.
    Schweitzer N; Vogel A
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):345-53. PubMed ID: 25966433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholangiocellular Carcinoma.
    Vogel A; Saborowski A
    Digestion; 2017; 95(3):181-185. PubMed ID: 28288474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.
    Jensen LH; Jakobsen A
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):589-600. PubMed ID: 21504326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future directions in the treatment of cholangiocarcinoma.
    Zhu AX
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.
    Valle JW; Furuse J; Jitlal M; Beare S; Mizuno N; Wasan H; Bridgewater J; Okusaka T
    Ann Oncol; 2014 Feb; 25(2):391-8. PubMed ID: 24351397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Systemic treatment of biliary tract cancer].
    Jensen LH; Larsen O
    Ugeskr Laeger; 2013 Oct; 175(42):2478-81. PubMed ID: 24629114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report.
    Marciano R; Servetto A; Bianco C; Bianco R
    J Med Case Rep; 2017 Sep; 11(1):273. PubMed ID: 28946921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of unresectable locally advanced intrahepatic cholangiocarcinoma that achieved pathological complete response after gemcitabine and S1 chemotherapy.
    Sumiyoshi T; Uemura K; Shintakuya R; Okada K; Otsuka H; Serikawa M; Ishii Y; Tsuboi T; Arihiro K; Takahashi S
    Clin J Gastroenterol; 2022 Dec; 15(6):1164-1168. PubMed ID: 36181621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
    Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
    Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
    Chung V
    Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach.
    Merath K; Tiwari A; Parikh AA; Pawlik TM
    Future Oncol; 2023 Dec; 19(39):2607-2621. PubMed ID: 38108100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door?
    Ricci AD; D'Alessandro R; Rizzo A; Schirizzi A; Vallarelli S; Ostuni C; Troiani L; Lolli IR; Lotesoriere C; Giannelli G
    Immunotherapy; 2023 May; 15(7):477-486. PubMed ID: 36950960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential targeted therapy for liver fluke associated cholangiocarcinoma.
    Vaeteewoottacharn K; Seubwai W; Bhudhisawasdi V; Okada S; Wongkham S
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):362-70. PubMed ID: 24408866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
    Kobayashi S; Terashima T; Shiba S; Yoshida Y; Yamada I; Iwadou S; Horiguchi S; Takahashi H; Suzuki E; Moriguchi M; Tsuji K; Otsuka T; Asagi A; Kojima Y; Takada R; Morizane C; Mizuno N; Ikeda M; Ueno M; Furuse J
    Cancer Sci; 2018 Aug; 109(8):2549-2557. PubMed ID: 29856900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors in cholangiocarcinoma.
    Beri N
    Immunotherapy; 2023 May; 15(7):541-551. PubMed ID: 37096964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs.
    Spolverato G; Glavas D; Hewitt DB; Brown ZJ; Capelli G; Bergamo F; Rizzato MD; Pawlik TM
    Expert Opin Pharmacother; 2022 Mar; 23(4):473-481. PubMed ID: 34964678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of curative resection after downsizing chemotherapy in initially unresectable locally advanced intrahepatic cholangiocarcinoma].
    Aoki Y; Suzuki T; Kato A; Shimizu H; Ohtsuka M; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takano S; Okamura D; Suzuki D; Sakai N; Kagawa S; Miyazaki M
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1509-11. PubMed ID: 25731235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring Molecular Mechanisms in the Second-Line Treatment of Biliary Tract Malignant Tumors.
    Liu Q; Zhang P; Li Q
    Discov Med; 2024 Jan; 36(180):48-60. PubMed ID: 38273745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of ivosidenib for the treatment of
    Tella SH; Mahipal A
    Expert Opin Pharmacother; 2022 Dec; 23(17):1879-1885. PubMed ID: 36257911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholangiocarcinoma.
    Squadroni M; Tondulli L; Gatta G; Mosconi S; Beretta G; Labianca R
    Crit Rev Oncol Hematol; 2017 Aug; 116():11-31. PubMed ID: 28693792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.